RxDoctor Payments Data

Rajesh Gupta, MD

Interventional Cardiology · Toledo, OHNPI 1477741197

Payments from drug & device makers

What this record shows

Abbott accounts for 73.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $1,331 and has fallen 78.3% since, to $289 in 2025. That places this record below the midpoint for interventional cardiology clinicians in OH, where the typical reported total is $4,547.

$2,057in general payments, 2019–2025

Across 27 payments — averaging $76.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Kestra Medical Technology Services, Inc.$123
  • E.r. Squibb & Sons, L.L.C.$104
  • Heartflow, Inc.$75
  • Abiomed$66
  • Inari Medical, Inc.$51
  • plus $121 from 5 others
$319,368in research payments, 2019–2025

Across 33 payments — averaging $9677.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$237K
  • Novartis$60K
  • EKOS Corporation$16K
  • Boston Scientific$8K

What the payments were for

  • Travel & lodging$1,12555%
  • Food & beverage$93245%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,057 in reported general payments places this provider in the 30th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$90,479
Medicare patients
415
Services billed
832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$256,820
EntrestoSacubitril/Valsartan86$130,341
XareltoRivaroxaban98$104,701
FarxigaDapagliflozin Propanediol70$81,009
Repatha SureclickEvolocumab85$67,685
JardianceEmpagliflozin45$55,546
Praluent PenAlirocumab17$24,105
Candesartan Cilexetil236$15,939
Icosapent Ethyl21$15,003
VascepaIcosapent Ethyl22$11,448
Ezetimibe192$6,622
Varenicline Tartrate26$6,349
Atorvastatin Calcium412$4,945
Metoprolol Succinate294$3,818
ClopidogrelClopidogrel Bisulfate247$3,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$36$130,34186 claims
AstraZenecaFarxiga$14$81,00970 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →